Results 71 to 80 of about 3,715,425 (177)

Efficacy and Safety of Glucagon-Like Peptide 1 Receptor Agonists in Parkinson Disease: A Systematic Review and Meta-Analysis. [PDF]

Brain Behav
Raza H, Nizam B, Padaniya A, Farid MA, Nabi A, Hasan MQ, Salih M, Patel AH, Inam N, Rehman MEU, Khan U, Alsubari AMA.   +11 more
europepmc   +1 more source

Racial and Ethnic Diversity in Clinical Trials for Disease Modifying Drugs in Parkinson Disease: A Systematic Review & Meta-Analysis. [PDF]

Mov Disord Clin Pract
Rodrigues FR, Bolner G, Ribeiro GBES, Koppanatham A, da Silva RV, Fearon C, Schumacher Schuh AF, Bayram E, Couto JBM, Ushe M, Di Luca DG.   +10 more
europepmc   +1 more source

Medication improves velocity, reaction time, and movement time but not amplitude or error during memory-guided reaching in Parkinson's disease. [PDF]

Physiol Rep
Trevarrow MP, Munoz MJ, Rivera YM, Arora R, Drane QH, Pal GD, Verhagen Metman L, Goelz LC, Corcos DM, David FJ.   +9 more
europepmc   +1 more source

Reflexive eye movement alterations are related to subclinical impulsive-compulsive behaviors in Parkinson's disease. [PDF]

Neurol Sci
Hapakova L, Straka I, Necpal J, Kusnirova A, Martis P, Valkovic P, Kosutzka Z.   +6 more
europepmc   +1 more source

ChemInform Abstract: SOME NEW PIPERAZINO DERIVATIVES AS ANTIPARKINSON AND ANTICONVULSANT AGENTS

, 1983
J. C. AGARWAL, K. P. BHARGAVA, M. SHARMA, G. P. GUPTA, K. SHANKER, C. NATH   +5 more
core   +1 more source

LASSO logistic regression and cluster analysis in predicting adherence and drug patterns among new users of monotherapy for antihypertensive drugs. [PDF]

J Hypertens
Li X, Tia MD, Bos JHJ, Schuiling-Veninga CCM, Hak E, Mubarik S.   +5 more
europepmc   +1 more source

Identifying Drugs Associated With Parkinson's Disease Risk Using Machine Learning. [PDF]

Basic Clin Pharmacol Toxicol
Pylkkö E, Courtois É, Paakinaho A, Hartikainen S, Kaasinen V, Elbaz A, Thiébaut ACM, Ahmed I, Tolppanen AM.   +8 more
europepmc   +1 more source

COMPARISON OF THE ELECTROENCEPHALOGRAPHIC AND MOTOR EFFECTS OF ORPHENADRINE, AN ANTIPARKINSON AGENT

Japanese Journal of Pharmacology, 1968
BAN, TAKASHI, HOJO, MASAKAZU
openaire   +3 more sources

Dyskinesia-Hyperpyrexia Syndrome in Parkinson's Disease May Benefit from GPi Deep Brain Stimulation: A Case Report. [PDF]

Tremor Other Hyperkinet Mov (N Y)
Huang SS, Ma LL, Sheng HS, Liu RP, Zhu SG, Xu SS, Sheng ML, Chen ZL, Zhang N, Zhang X, Wang JY.   +10 more
europepmc   +1 more source

Reducing delays in time-critical medications for Parkinson's disease: a multifaceted, multiprofessional quality improvement project. [PDF]

BMJ Open Qual
Fisher J, Scott C.
europepmc   +1 more source